Caidya
↗Morrisville, USA
Caidya is a global, full-service contract research organization (CRO) that supports biopharma innovators through the entire clinical development lifecycle. Formed in 2021 from the merger of dMed and Clinipace, the company provides personalized clinical research services, including pre-IND strategy, clinical operations, regulatory affairs, and post-marketing surveillance.
Caidya leverages proprietary clinical technology, such as the 'Caidya Clarity' platform, to enhance trial transparency, data-driven decision-making, and operational efficiency. The company operates in over 50 countries and maintains a strong focus on complex, multi-regional trials, particularly in oncology, hematology, rare diseases, pediatrics, and cell/gene therapy.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$373M
Investors:Rubicon Founders, Qiming Venture Partners, Fidelity Investments, SpringHill Management
PIPELINE
Stage:N/A
Lead Drug Stage:N/A
Modalities:Small molecule, Cell therapy, Gene therapy
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Medidata (Technology partnership for clinical trial innovation)
COMPETITION
Position:Challenger
Competitors:WuXi AppTec, Precision Medicine Group, ANI Pharmaceuticals
LEADERSHIP
Key Executives:
Barbara Lopez Kunz - CEO
Board Members:David M. Glaccum
LINKS
Website:caidya.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Caidya and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Caidya. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.